Corient Private Wealth
CYTK icon

Corient Private Wealth’s Cytokinetics CYTK Stock Holding History

Corient Private Wealth’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$470K Sell
7,148
-30,080
-81% -$1.91M ﹤0.01% 2064
2025
Q4 		$893K Buy
37,228
+32,415
+673% +$2.02M ﹤0.01% 1943
2025
Q3 		$265K Buy
+4,813
New +$198K ﹤0.01% 2196
2025
Q2 		– Sell
-6,416
Closed -$258K – 2460
2025
Q1 		$258K Buy
+6,416
New +$295K ﹤0.01% 1936
2024
Q2 		– Sell
-3,165
Closed -$222K – 2332
2024
Q1 		$222K Sell
3,165
-1,766
-36% -$137K ﹤0.01% 2051
2023
Q4 		$412K Buy
+4,931
New +$179K ﹤0.01% 1709

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corient Private Wealth's CYTK Position: Q1 2026 in Review

Corient Private Wealth reduced its Cytokinetics (CYTK) stake by 81% in Q1 2026, selling an estimated $1.91M and leaving 7,148 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

Corient Private Wealth first reported a position in CYTK in Q4 2023 and has held it in 6 quarters since. The position peaked at $893K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Corient Private Wealth held 7,148 shares of Cytokinetics worth $470K as of Q1 2026.
  • Corient Private Wealth sold 30,080 Cytokinetics shares in Q1 2026, an estimated $1.91M.
  • Cytokinetics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2064 holding.
  • Corient Private Wealth first reported a position in Cytokinetics in Q4 2023 and has held it in 6 quarters since.
  • Corient Private Wealth's Cytokinetics position peaked at $893K in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.